Immunotherapy News and reporting on cancer immunotherapy. Jan 20, 2023 Astellas' Zolbetuximab Plus Chemo Benefits CLDN18.2-Positive, HER2-Negative Gastric Cancer Patients Premium Jan 18, 2023 Penn Scientists Testing Out CAR T-Cell Therapy Gel to Prevent Breast Cancer Recurrence Post-Surgery Premium Jan 17, 2023 Elicio Therapeutics to Merge With Angion Biomedica Jan 17, 2023 PamGene, Alithea Genomics, Lausanne University get €1M for Pan-Cancer Blood Test Jan 11, 2023 Texas Research Institute, TGen, OncoHost Partner to ID Lung Cancer Resistance Mechanisms Jan 10, 2023 Immunocore Unveils New T-Cell Receptor Therapy Candidates, Estimates $140M in 2022 Kimmtrak Sales Jan 10, 2023 Could PD-L1/2 Structural Variants be the Next Pan-Cancer Predictive Immunotherapy Biomarker? Premium Jan 10, 2023 NextPoint Therapeutics Raises $80M in Series B Financing Jan 9, 2023 GreenLight Biosciences, EpiVax Therapeutics Partner to Develop Personalized Cancer Vaccines Jan 6, 2023 BioNTech, UK Government to Expand Access to Personalized mRNA Cancer Vaccines in England Dec 30, 2022 Esophageal Cancer Molecular Study Highlights Tumor Subtypes, Treatment Response Markers Dec 28, 2022 Gilead Sciences Acquires Remaining Rights to Anti-CCR8 Antibody From Jounce Therapeutics Dec 22, 2022 Gilead Sciences, Arcus Biosciences Tout Domvanalimab NSCLC Data as Good News for Anti-TIGIT Approach Premium Dec 22, 2022 OneChain Immunotherapeutics to Launch CD1a-Targeting CAR T-Cell Therapy Trial in T-Cell Leukemia Dec 20, 2022 Gilead Sciences to Acquire Cell Therapy Biotech Tmunity Therapeutics Dec 20, 2022 Moderna's Oncology Aspirations Grow With mRNA Vaccine Success in Melanoma Premium Dec 15, 2022 Immix Biopharma Forms New Subsidiary, In-Licenses Multiple Myeloma CAR T-Cell Therapy Dec 13, 2022 Gilead's Yescarta Safe and Effective for CNS Lymphoma Patients, Pilot Study Shows Premium Dec 12, 2022 T-Cell Subpopulations in Blood May Help Predict Immune Checkpoint Immunotherapy Side Effects Dec 11, 2022 Bristol Myers Squibb, 2seventybio's Abecma Shows Benefit in High-Risk Multiple Myeloma Patients Premium Load More Breaking News Ratio Therapeutics Raises $20M in Series A Financing Guardant Health, AnHeart Tx to Develop Blood- and Tissue-Based CDx for NSCLC Drug Ellipses Pharma Cleared by FDA to Open Phase I/II AML Trial Survey Reveals Changing Genetic Testing Patterns, Persistent Disparities in Precision Oncology Amgen's Lumakras Sales Increased 58 Percent in Q4 2022 Coeptis Therapeutics, University of Pittsburgh Studying SNAP-CAR Therapy in HER2-Positive Cancers
